Retinoic Acid Receptor Activation Reduces Metastatic Prostate Cancer Bone Lesions by Blocking the Endothelial-to-Osteoblast Transition.
Guoyu YuPaul G CornPeng-Fei ShenJian H SongYu-Chen LeeSong-Chang LinJing PanSandeep K AgarwalTheocharis PanaretakisMaurizio PacificiChristopher L LogothetisSue-Hwa LinSue-Hwa LinPublished in: Cancer research (2022)
This study provides mechanistic insights into how RAR agonists suppress prostate cancer-induced bone formation and offers a rationale for developing RAR agonists for prostate cancer bone metastasis therapy. See related commentary by Bhowmick and Bhowmick, p. 2975.